- |||||||||| Copegus (ribavirin) / Bausch Health, Sovaldi (sofosbuvir) / Gilead
Preclinical, Journal: Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro. (Pubmed Central) - Jul 29, 2020
Furthermore, SOF and 2CMG, with four interferons (IFN-α2b, IFN-λ1, IFN-λ2 and IFN-λ3), inhibited HEV growth efficiently and cleared HEV in cultured cells. These results suggest that, in combination with RBV or interferons, SOF and 2CMG would be promising bases for developing anti-HEV nucleos(t)ide analogs.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. (Pubmed Central) - Jul 29, 2020
These data suggest that S282T is the only known substitution that confers detectable resistance to sofosbuvir in vitro. Sofosbuvir displayed potent antiviral activity across a diverse range of NS5B mutants and HCV clinical isolates in multiple subtypes of genotypes 1 to 6.
- |||||||||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Journal: Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. (Pubmed Central) - Jul 25, 2020
DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in "difficult to treat" HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] TREATMENT OF A PATIENT WITH GENOTYPE 7 HEPATITIS C VIRUS INFECTION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5632;
At 12 weeks after the end of treatment the HCV RNA was undetectable confirming sustained virological response. This is a case of successful treatment with sofosbuvir and velpatasvir of a patient with a rare HCV genotype only reported in individuals from Democratic Republic of the Congo.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SUCCESSFUL TREATMENT OF HEPATITIS C IN AN EGYPTIAN PATIENT WITH POLYCYTHEMIA RUBRA VERA WITH DIRECT-ACTING ANTIVIRALS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5631;
The diagnosis of PRV was confirmed and she was kept on hydroxyurea 500mg twice daily, in addition to pentoxifylline, and aspirin 100mg once daily for fear of thrombotic complications...According to national protocols, she received Sofosbuvir 400mg, Daclatasvir 60mg and Ribavirin (RBV) 800mg once daily for 12 weeks, with monthly follow-up...At week 12, since hemoglobin level became stable (14.6 g/dl) and PLT was 575x103/mm3, the dose of hydroxyurea was increased to thrice daily, anagrelide was reduced to twice daily, and pentoxifylline was stopped. The patient achieved sustained virological response by HCV PCR done 12 weeks after end of treatment, and her labs (including liver functions and blood picture) remained stable.
- |||||||||| pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] HEPATITIS B REACTIVATION DURING HEPATITIS C TREATMENT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4981;
Our results suggest that HCV patients with HBsAg negative and anti-HBc positive serology are a safe population to treat with DAA, with no apparent risk of HBV reactivation. In HBsAg positive patients, the alert for the use of concomitant prophylactic HBV therapy is reinforced, since 2 in 3 had reactivation.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] ELIMINATION OF HEPATITIS C VIRUS INFECTION AMONG PWUIDS AS PART OF THE NATIONAL EGYPTIAN MACROELIMINATION TEST AND TREAT PROGRAM (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4977;
A relatively high efficacy and safety to sofosbuvir-based treatment regimens among HCV infected PWUDs, when compared with non-drug users. Studies on the best choice of HCV treatment combination regimen for Egyptian PWUDs are essential to inform a targeted coverage of PWUDs, which is an urgently needed policy to eliminate HCV infections among this key population and its importance to reduce social and economic harm to individuals and society.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SAFETY AND PREGNANCY OUTCOME OF ANTI-HCV DIRECT-ACTING ANTIVIRALS: REAL-LIFE DATA FROM AN EGYPTIAN COHORT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4972;
All patients received 12-week anti-HCV treatment regimens which included: sofosbuvir plus daclatasvir (SOF/DCV) in 95 patients (95%), SOF/DCV plus ribavirin (RBV) in 3 patients and paritaprevir/ritonavir/ombitasvir plus RBV in 2 patients. In our cohort of pregnant females, anti-HCV DAAs were safe without fetal anomalies or related adverse pregnancy outcomes.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] TREATMENT OF A PATIENT WITH GENOTYPE 7 HEPATITIS C VIRUS INFECTION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3656;
At 12 weeks after the end of treatment the HCV RNA was undetectable confirming sustained virological response. This is a case of successful treatment with sofosbuvir and velpatasvir of a patient with a rare HCV genotype only reported in individuals from Democratic Republic of the Congo.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SUCCESSFUL TREATMENT OF HEPATITIS C IN AN EGYPTIAN PATIENT WITH POLYCYTHEMIA RUBRA VERA WITH DIRECT-ACTING ANTIVIRALS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3655;
The diagnosis of PRV was confirmed and she was kept on hydroxyurea 500mg twice daily, in addition to pentoxifylline, and aspirin 100mg once daily for fear of thrombotic complications...According to national protocols, she received Sofosbuvir 400mg, Daclatasvir 60mg and Ribavirin (RBV) 800mg once daily for 12 weeks, with monthly follow-up...At week 12, since hemoglobin level became stable (14.6 g/dl) and PLT was 575x103/mm3, the dose of hydroxyurea was increased to thrice daily, anagrelide was reduced to twice daily, and pentoxifylline was stopped. The patient achieved sustained virological response by HCV PCR done 12 weeks after end of treatment, and her labs (including liver functions and blood picture) remained stable.
- |||||||||| pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] HEPATITIS B REACTIVATION DURING HEPATITIS C TREATMENT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3005;
Our results suggest that HCV patients with HBsAg negative and anti-HBc positive serology are a safe population to treat with DAA, with no apparent risk of HBV reactivation. In HBsAg positive patients, the alert for the use of concomitant prophylactic HBV therapy is reinforced, since 2 in 3 had reactivation.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] ELIMINATION OF HEPATITIS C VIRUS INFECTION AMONG PWUIDS AS PART OF THE NATIONAL EGYPTIAN MACROELIMINATION TEST AND TREAT PROGRAM (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3001;
A relatively high efficacy and safety to sofosbuvir-based treatment regimens among HCV infected PWUDs, when compared with non-drug users. Studies on the best choice of HCV treatment combination regimen for Egyptian PWUDs are essential to inform a targeted coverage of PWUDs, which is an urgently needed policy to eliminate HCV infections among this key population and its importance to reduce social and economic harm to individuals and society.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SAFETY AND PREGNANCY OUTCOME OF ANTI-HCV DIRECT-ACTING ANTIVIRALS: REAL-LIFE DATA FROM AN EGYPTIAN COHORT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2996;
All patients received 12-week anti-HCV treatment regimens which included: sofosbuvir plus daclatasvir (SOF/DCV) in 95 patients (95%), SOF/DCV plus ribavirin (RBV) in 3 patients and paritaprevir/ritonavir/ombitasvir plus RBV in 2 patients. In our cohort of pregnant females, anti-HCV DAAs were safe without fetal anomalies or related adverse pregnancy outcomes.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] TREATMENT OF A PATIENT WITH GENOTYPE 7 HEPATITIS C VIRUS INFECTION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1672;
At 12 weeks after the end of treatment the HCV RNA was undetectable confirming sustained virological response. This is a case of successful treatment with sofosbuvir and velpatasvir of a patient with a rare HCV genotype only reported in individuals from Democratic Republic of the Congo.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SUCCESSFUL TREATMENT OF HEPATITIS C IN AN EGYPTIAN PATIENT WITH POLYCYTHEMIA RUBRA VERA WITH DIRECT-ACTING ANTIVIRALS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1671;
The diagnosis of PRV was confirmed and she was kept on hydroxyurea 500mg twice daily, in addition to pentoxifylline, and aspirin 100mg once daily for fear of thrombotic complications...According to national protocols, she received Sofosbuvir 400mg, Daclatasvir 60mg and Ribavirin (RBV) 800mg once daily for 12 weeks, with monthly follow-up...At week 12, since hemoglobin level became stable (14.6 g/dl) and PLT was 575x103/mm3, the dose of hydroxyurea was increased to thrice daily, anagrelide was reduced to twice daily, and pentoxifylline was stopped. The patient achieved sustained virological response by HCV PCR done 12 weeks after end of treatment, and her labs (including liver functions and blood picture) remained stable.
- |||||||||| pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] HEPATITIS B REACTIVATION DURING HEPATITIS C TREATMENT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1021;
Our results suggest that HCV patients with HBsAg negative and anti-HBc positive serology are a safe population to treat with DAA, with no apparent risk of HBV reactivation. In HBsAg positive patients, the alert for the use of concomitant prophylactic HBV therapy is reinforced, since 2 in 3 had reactivation.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] ELIMINATION OF HEPATITIS C VIRUS INFECTION AMONG PWUIDS AS PART OF THE NATIONAL EGYPTIAN MACROELIMINATION TEST AND TREAT PROGRAM (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1017;
A relatively high efficacy and safety to sofosbuvir-based treatment regimens among HCV infected PWUDs, when compared with non-drug users. Studies on the best choice of HCV treatment combination regimen for Egyptian PWUDs are essential to inform a targeted coverage of PWUDs, which is an urgently needed policy to eliminate HCV infections among this key population and its importance to reduce social and economic harm to individuals and society.
- |||||||||| Daklinza (daclatasvir) / BMS
[VIRTUAL] SAFETY AND PREGNANCY OUTCOME OF ANTI-HCV DIRECT-ACTING ANTIVIRALS: REAL-LIFE DATA FROM AN EGYPTIAN COHORT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1012;
All patients received 12-week anti-HCV treatment regimens which included: sofosbuvir plus daclatasvir (SOF/DCV) in 95 patients (95%), SOF/DCV plus ribavirin (RBV) in 3 patients and paritaprevir/ritonavir/ombitasvir plus RBV in 2 patients. In our cohort of pregnant females, anti-HCV DAAs were safe without fetal anomalies or related adverse pregnancy outcomes.
- |||||||||| Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS
Clinical, Journal: Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. (Pubmed Central) - Jul 16, 2020
In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients...The patients received one of the following 3 regimens for 12 weeks; PEG-INF/SOF, Simeprevir/SOF (SIM/SOF), and Daclatasvir/SOF (DCV/SOF)...A SIM/SOF regimen provokes the highest SVR12 in PEG-INF/RBV-experienced chronic HCV patients. Retreatment with PEG-INF/SOF in PEG-INF/RBV-experienced chronic HCV patients has a high probability of treatment failure.
- |||||||||| velpatasvir (GS-5816) / Gilead
Preclinical, Journal: In Vitro Resistance Profile of Hepatitis C Virus NS5A Inhibitor Velpatasvir in Genotypes 1 to 6. (Pubmed Central) - Jul 11, 2020
High level resistance was observed for C92T and Y93H/N in subtype 2b, Y93H/S in 3a, and L31V and P32A/L/Q/R in 6a, and several double mutants in these subtypes. Overall, velpatasvir maintained activity against most common RASs that are known to confer resistance to first generation NS5A inhibitors.
- |||||||||| pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Clinical, Journal: Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. (Pubmed Central) - Jul 4, 2020
Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.
- |||||||||| Clinical, Journal: Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report. (Pubmed Central) - Jul 4, 2020
Here, we suggest well-tolerated sofsobuvir-based treatment regimen in patient infected with HBV, HCV, and HEV. Twelve weeks long treatment with sofsobuvir, daclatasvir, ribavirin, and tenofovir resulted in sustained virological response (SVR) and cleared HBV, HCV, and HEV in diabetic and asthmatic patient.
- |||||||||| Daklinza (daclatasvir) / BMS
Journal: Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed. (Pubmed Central) - Jul 3, 2020
No significant changes in MELD score. Treatment of HCV-related LC patients with sofosbuvir and daclatasvir with or without ribavirin for 3 or 6 months showed high SVR and significant improvement in CP score, but still at risk of HCC even if treated and should be followed up regularly according to screening programs with special meticulous attention to those with non-SVR.
|
